

Protein Kinase 2012 Signalling Success: 5th SCI-RSC symposium on kinase inhibitor design

Monday 21 - Tuesday 22 May 2012 Accelrys, Cambridge Science Park, Cambridge, UK

RSC | Advancing the Chemical Sciences

Organised by SCI's Fine Chemicals Group and the RSC's Biological and Medicinal Chemistry Sector in Partnership with Accelrys





Monday 21 May

08:30	Registration and coffee	
09:20	Opening remarks	
09:30	The ABC of kinase conformations Henrik Möbitz (Novartis, Switzerland)	
10:15	Structure-based design for kinases guided by fragment-molecular- orbital and water analysis Richard Law (Evotec, UK)	
11:00	Refreshments	
11.30	Mass spectrometry based proteomics approaches for mode of action analysis of kinase inhibitors Christian Eckert (Evotec, Germany)	
12:15	Speaker to be announced	
13:00	Lunch	
14.00	Non-ATP competitive kinase inhibitors: potential and limitations Doriano Fabbro (Novartis, Switzerland)	
14.45	Inhibition of B-RAF kinase as a therapeutic approach to melanoma Speaker to be announced (The Institute of Cancer Research, UK)	
15:15	Discovery of AZD5363, an orally bioavailable, potent inhibitor of AKT kinases Richard Luke (AstraZeneca, UK)	
16.00	Refreshments	
16:30	Presentation of posters followed by networking reception	

Please pass this flyer onto a colleague







Tuesday 22 May

09:00 Structure based design of novel allosteric MEK templates: optimising a critical H-bonding interaction

Robert Heald (Argenta, UK)

- 09:45 A snapshot of kinase research at Roche Nutley:
 - 1) developing selective kinase inhibitors for inflammation targets
 - 2) kinase inhibitors for chemical biology

Michael Soth (Roche, US)

10:30 Novel triazolopyridine compounds as selective JAK1 kinase inhibitors: from hit to clinical candidate (GLPG0634)

Christel Menet (Galapagos, Belgium)

- 11.15 Refreshments
- 11:45 Kinobeads[™] enabled discovery of CZC54109 a highly selective and orally efficacious inhibitor of mTOR

 Andrew Cansfield (Cellzome, UK)
- 12.30 The discovery of potent antiviral agents for the treatment of picornavirus infections by a novel mechanism

 Angus MacLeod (BioFocus, UK)
- 13:15 Lunch
- 14:15 The discovery of AZD4547: an orally bioavailable, potent and selective N-(5-pyrazolyl)benzamide FGFR1-3 inhibitor
 Andrew Thomas (AstraZeneca, UK)
- 15:00 Inhaled PI3Kδ inhibitors for respiratory indications

Nicole Hamblin (GlaxoSmithKline, UK)

15:45 Discovery of substituted 2-aminopyrimidinones as novel and selective

inhibitors of PI3Kδ Robert Owen (Pfizer, UK)

16:30 Concluding Remarks







Confirmation of protein kinases as clinically relevant targets has been demonstrated by the success of drugs in the oncology market.

The year 2011 saw the approval of three new drugs that target various types of cancer and ongoing clinical trials suggest that there is a healthy pipeline of kinase inhibitors to follow. This symposium will detail recent progress in the area of Protein Kinases (PKs) and address the challenges and issues associated with converting kinase inhibitors into clinical compounds in oncology but also in non-oncology settings. There will be talks on how some of the latest technologies are being applied to PK inhibitor programmes to help identify the next generation of drugs that act on this family of enzymes as well as the first disclosure of some recent clinical candidates.

Attendees

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

Please note there are a limited number of spaces at the conference.

Posters

A poster session will take place at the end of Day 1. A one-page abstract should be submitted to jacqui.colgate@soci.org by 31st March 2012. When submitting posters delegates should indicate whether they would be prepared to give a 1-2 slide summary of their poster in a formal presentation session that will take place on Day 1.

Venue

Accelrys is located at 334 Cambridge Science Park, Cambridge CB4 0WN. Tel no: 01223 228500

Accommodation

Please note that accommodation is not included in the registration fees and that transportation to and from the venue is not provided. Suggestions for hotels can be found at: http://accelrys.com/about/locations/directions-cambridge.html and there are hotels a short taxi ride or 10 minute walk from the venue. Parking is available on the Accelrys site. Spaces are limited so please ensure you reserve one if required at time of registration.

Travel to Cambridge is convenient by road or rail. Accelrys is in the Cambridge Science Park. There are frequent train services to Cambridge from London Kings Cross and Liverpool Street Stations. The nearest international airport is London Stansted (30 miles) which has rail and coach links to Cambridge. From London Heathrow and Gatwick Airports there are express rail links to central London for onward rail journeys as above. There are also coach links from both airports direct to Cambridge.



Organisers

Kathryn Bell (Cellzome, UK)
Stephen East (Evotec, UK)
Roger Griffin (University of Newcastle, UK)
Mark Hanson (Accelrys, UK)
John Harris (CJH Consultants, UK)
Keith Jones (Institute of Cancer Research, UK)

Jackie Macritchie (BioFocus, UK) Parminder Ruprah (Takeda, UK) Andrew Thomas (AstraZeneca, UK) Adele Willacy (Accelrys, UK)

ponso

Accelrys and its predecessors have been based in Cambridge since 1989. The original Cambridge operation was a startup software company that emerged from the University's Materials Science Department. The company retains close ties with the local academic and high tech community. Accelrys are located on the well known Cambridge Science Park.



The RSC is a learned society and professional body for the chemical sciences Members of the RSC come from diverse areas of the chemical sciences and are employed in a wide variety of professions worldwide.

The Biological & Medicinal Chemistry Sector (BMCS), as part of the Industry & Technology Division, aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules.

Further information about the activities of the BMCS and benefits of the RSC membership can be found at www.rsc.org/bmcs

Biological & Medicinal

Chemistry Syctor

SCI is an international, independent charity whose remit is to promote the application of science for the benefit of society.

SCI is the publisher of many well respected journals and industry leader Chemistry & Industry magazine (C&I). SCI can offer a network of contacts spanning education, science and business, an in-depth knowledge of chemical related industries together with a rolling programme of conferences, awards and scholarships to help further knowledge and support those involved in the sector no matter what stage of their careers.

For more information on the benefits of joining SCI please go to www.soci.org/membership







Protein Kinase 2012 21-22 May 2012 @ Accelrys, Cambridge, UK If you would like to become a member of SCI today, please tick the box below and you can benefit from the SCI discounted member rate on booking this conference			
I would like to become a member of SCI Please tick appropriate box below Booking Rate before 22 Apr 2012 SCI/RSC Member	Booking Rate after 22 Apr 2012 SCI/RSC Member		
SCI/RSC membership number (if applicable)			
Surname First Name			
Title Mr/Mrs/Dr/Prof/OtherPosition			
Organisation			
Address			
	Postcode		
Tel			
Email			
Special requirements: (dietary/access/other)			
Signature	Date		
There are 3 ways to pay: 1. Online at www.soci.org/events (multiple delegates can easily be booked) 2. Cheques made payable to 'SCI' should be drawn in GB£ & enclosed with this form 3. Credit Card. Please debit £ from my Mastercard/ Visa/ Amex (please circle) Card Expiry Date / Signed			
Please return completed forms to: SCI Conference Dept, 14/15 Belgrave Square, London, SW1X 8PS T: +44 (0) 20 7598 1561; F: +44 (0) 20 7235 7743; E: conferences@soci.org Cancellations: Received in writing 1 to 3 weeks prior to the meeting will be subject to a 20% administration charge Refunds cannot be made for cancellations received after this period although substitutions may be made. Should unforeseen circumstances occur, SCI reserves the right to alter the content of the programme and cancel or postpone and			

of its meetings without notice or, in the case of complete cancellation, liability to enrolled delegates other than return of fees.

Data Protection: The personal information included on this form will be used by the SCI only and will not be disclosed to any third parties. Please tick if you do not wish to be sent details of any future similar meetings or other SCI services.

Register online at: www.soci.org/events